

PATENT**TITLE**

**Identification of a JAK2 mutation involved in
Vaquez Polyglobulia**

REGISTRANTS

- ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE (INSERM)
- INSTITUT GUSTAVE ROUSSY (IGR)
- UNIVERSITÉ DE VERSAILLES-SAINT QUENTIN YVELINES
- UNIVERSITÉ PARIS-SUD

ABSTRACT

The present invention concerns the V617F variant of the protein-tyrosine kinase JAK2, said variant being responsible for Vaquez Polyglobulia. The invention also relates to a first intention diagnostic method for erythrocytosis and thrombocytosis allowing their association with myeloproliferative disorders, or to the detection of the JAK2 V617F variant in myeloproliferative disorders allowing their reclassification in a new nosological group, and to the identification of specific inhibitors and siRNA.